128 related articles for article (PubMed ID: 10895986)
1. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.
Shimoda K; Morita S; Hirokane G; Yokono A; Someya T; Takahashi S
Pharmacol Toxicol; 2000 Jun; 86(6):245-9. PubMed ID: 10895986
[TBL] [Abstract][Full Text] [Related]
2. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
[TBL] [Abstract][Full Text] [Related]
3. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
[TBL] [Abstract][Full Text] [Related]
4. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline.
Morita S; Shimoda K; Someya T; Yoshimura Y; Kamijima K; Kato N
J Clin Psychopharmacol; 2000 Apr; 20(2):141-9. PubMed ID: 10770451
[TBL] [Abstract][Full Text] [Related]
5. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients.
Shimoda K; Someya T; Yokono A; Morita S; Hirokane G; Takahashi S; Okawa M
J Clin Psychopharmacol; 2002 Aug; 22(4):371-8. PubMed ID: 12172336
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
[TBL] [Abstract][Full Text] [Related]
7. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
[TBL] [Abstract][Full Text] [Related]
9. Factors Affecting Steady-state Plasma Concentrations of Enantiomeric Mirtazapine and its Desmethylated Metabolites in Japanese Psychiatric Patients.
Hayashi Y; Watanabe T; Aoki A; Ishiguro S; Ueda M; Akiyama K; Kato K; Inoue Y; Tsuchimine S; Yasui-Furukori N; Shimoda K
Pharmacopsychiatry; 2015 Nov; 48(7):279-85. PubMed ID: 26595747
[TBL] [Abstract][Full Text] [Related]
10. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.
Bergmann TK; Bathum L; Brosen K
Eur J Clin Pharmacol; 2001 May; 57(2):123-7. PubMed ID: 11417443
[TBL] [Abstract][Full Text] [Related]
11. Lack of desipramine toxicity with citalopram.
Ashton AK
J Clin Psychiatry; 2000 Feb; 61(2):144. PubMed ID: 10732663
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1998 Oct; 64(4):384-90. PubMed ID: 9797795
[TBL] [Abstract][Full Text] [Related]
13. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
14. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
16. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
[TBL] [Abstract][Full Text] [Related]
17. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
Sawamura K; Suzuki Y; Someya T
Eur J Clin Pharmacol; 2004 Oct; 60(8):553-7. PubMed ID: 15349705
[TBL] [Abstract][Full Text] [Related]
18. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of desipramine metabolism.
Musa MN; Miescke KJ
Int J Clin Pharmacol Ther; 1994 Mar; 32(3):126-30. PubMed ID: 8205373
[TBL] [Abstract][Full Text] [Related]
20. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.
Baumann P; Broly F; Kosel M; Eap CB
Pharmacopsychiatry; 1998 Mar; 31(2):72. PubMed ID: 9562213
[No Abstract] [Full Text] [Related]
[Next] [New Search]